EUVIMEDEUVIMED entdecken
Netzwerk-Metaanalyse

Cardiovascular efficacy and safety of antidiabetic agents: A network meta‐analysis of randomized controlled trials

Minji Sohn, Juan P Frias, Soo Lim iD

Diabetes, Obesity and Metabolism · 2023

DOI: 10.1111/dom.15251 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Minji Sohn und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Kor…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Thiazolidinediones, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 93 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

An important characteristic of glucose‐lowering therapies (GLTs) is their ability to prevent cardiovascular complications. We aimed to investigate the cardiorenal efficacy and general safety of GLTs. Materials and Methods Multicentre, randomized, clinical trials that included over 100 participants comparing antidiabetic agents with a placebo or a different antidiabetic agent and reporting major adverse cardiovascular events (MACEs), or primarily reporting heart failure, were searched in the PubMed, Embase and Cochrane databases. Data were extracted independently for random‐effects network meta‐analyses to calculate the hazard ratio estimates.

Results

Forty‐three trials that compared nine types of GLTs were included in the present analysis. The risk of three‐point MACE was reduced in the presence of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2is) and thiazolidinedione therapy compared with the placebo, dipeptidyl peptidase‐4 inhibitors, or insulin therapy. GLP‐1 RAs were favourable for cardiovascular and renal outcomes. SGLT‐2is reduced renal outcomes by ~40%, which was superior to other GLTs. Thiazolidinedione therapy increased the risks of hospitalization for heart failure and had no benefits on mortality. Adverse events leading to drug discontinuation were higher with GLP‐1 RAs and thiazolidinediones than placebo.

Conclusions

GLP‐1 RAs, SGLT‐2is and thiazolidinediones reduced three‐point MACE compared with other GLTs. Each drug class had unique advantages and disadvantages.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2ThiazolidinedionesDipeptidyl-Peptidase IV InhibitorsHeart FailureCardiovascular DiseasesHumansHypoglycemic AgentsRandomized Controlled Trials as TopicGlucagon-Like Peptide 1GlucoseGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

adverse reactionshypoglycaemic agentsmajor adverse cardiac eventsnetwork meta-analysisrenal outcomes

Substanzen

Hypoglycemic Agents2,4-thiazolidinedioneSodium-Glucose Transporter 2 InhibitorsThiazolidinedionesDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide 1GlucoseGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
  • National Research Institute, Metro Medical Mall, Los Angeles, California, USA.

ORCID-Profile: Soo Lim

Zitieren

APA

Sohn, M., Frias, J. P., & Lim, S. (2023). Cardiovascular efficacy and safety of antidiabetic agents: A network meta‐analysis of randomized controlled trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15251

Vancouver

Sohn M, Frias JP, Lim S. Cardiovascular efficacy and safety of antidiabetic agents: A network meta‐analysis of randomized controlled trials. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15251

BibTeX
@article{Sohn2023,
  author = {Sohn, Minji and Frias, Juan P and Lim, Soo},
  title = {Cardiovascular efficacy and safety of antidiabetic agents: A network meta‐analysis of randomized controlled trials},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  doi = {10.1111/dom.15251}
}
Kostenlos starten →